Myogen Target definition

Myogen Target means any Target Controlled by Myogen and identified and/or synthesized by Myogen, its Affiliates, and/or its external academic collaborators in the Field, excluding any Targets within Myogen's HDAC inhibitor program. A list of Myogen Targets as of the Effective Date is set forth on Schedule 1.25 appended hereto. Such Schedule [/\#/\]CONFIDENTIAL TREATMENT REQUESTED
Sample 1Sample 2
Myogen Target shall have the meaning set forth in the Collaboration Agreement.
Sample 1Sample 2
Myogen Target shall have the meaning set forth in Section 1.25 of the Collaboration Agreement. [/\#/\]CONFIDENTIAL TREATMENT REQUESTED
Sample 1Sample 2

Examples of Myogen Target in a sentence

  • The parties expressly agree that the royalties and milestones hereunder are in consideration of the use of Myogen Technology to identify, synthesize, select or find useful the Development Candidate as having a desired therapeutic effect on any Myogen Target or Collaboration Target.

  • In the event that an Active Compound fails in development, any milestone payments previously paid with respect to such Active Compound shall be fully creditable toward the same milestone due with respect to another Active Compound that acts on the same Myogen Target.

  • In the event that a Myogen Compound, Collaboration Compound or NIBRI Compound fails in development, any milestone payments previously paid with respect to such Myogen Compound, Collaboration Compound or NIBRI Compound shall be fully creditable toward the same milestone due with respect to another Myogen Compound, Collaboration Compound or NIBRI Compound advanced as a lead Compound in place of the failed Compound that acts on the same Myogen Target or Collaboration Target.

  • In the event that an Active Compound fails in development, any milestone payments previously paid with respect to such Active Compound shall be fully creditable toward the same milestone due with respect to another Active Compound that acts on the same Myogen Target or Collaboration Target.

  • In the event that NIBRI elects to discontinue any Research Program with respect to any Myogen Target for which the parties have identified a NIBRI Compound that acts on such Target, and NIBRI subsequently contemplates collaborating with a Third Party with respect to development and/or commercialization of the NIBRI Compound, NIBRI shall give Myogen written notice of the same.

  • Except as disclosed in writing between the parties to this Agreement or their respective agents, as of the Effective Date, to Myogen's knowledge there are no issued patents or pending patent applications that, if issued, would be infringed by the development, manufacture, use or sale of any Myogen Compound or Myogen Target, as applicable, pursuant to this Agreement.

  • In the normal course of development, any Development Candidate may be dropped from development for valid scientific or medical reasons provided to Myogen by NIBRI in writing and may be replaced (at the sole discretion of NIBRI and/or its Affiliates) with another Development Candidate having a therapeutic action on the same Myogen Target or Collaboration Target, and such occurrence shall not constitute a failure of due diligence.

  • In the normal course of development, any Development Candidate may be dropped from development for valid scientific or medical reasons provided to Myogen by NIBRI in writing and may be replaced (at the sole discretion of NIBRI and/or its Affiliates) with another Development Candidate having a therapeutic action on the same Myogen Target, and such occurrence shall not constitute a failure of due diligence.

  • Except as explicitly set forth below, pre-clinical milestone payments shall be payable on only one Active Compound per Myogen Target, and clinical milestones shall be payable only once on a particular Active Compound, even though that Active Compound may be subsequently developed for indications other than those for which regulatory approval was initially sought.

  • The parties expressly agree that the royalties and milestones hereunder are in consideration of the use of Myogen Technology to identify, synthesize, select or find useful the Development Candidate as having a [..**..] Confidential Treatment Requested 27 desired therapeutic effect on any Myogen Target.

Related to Myogen Target

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • KPI Target means the acceptable performance level for a KPI as set out in each KPI;

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Licensed Compound means [***].

  • GSK has the meaning set forth in the preamble.

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Diagnostic Product means any test or assay for diagnosing or detecting a disease, disorder, medical condition, or symptom.

  • ISIS means the department’s individualized services information system.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Acquisition Target means any Person becoming a Subsidiary of the Company after the date hereof; any Person that is merged into or consolidated with the Company or any Subsidiary of the Company after the date hereof; or any Person with respect to which all or a substantial part of that Person’s assets are acquired by the Company or any Subsidiary of the Company after the date hereof.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Research Program has the meaning set forth in Section 2.1.

  • Novartis shall have the meaning set forth in the Preamble.

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Phase I Clinical Study means, as to a particular Licensed Product, an initial clinical study in humans with the purpose of assessing the Licensed Product’s safety, tolerability, toxicity, pharmacokinetics or other pharmacological properties.